<DOC>
	<DOCNO>NCT02493946</DOCNO>
	<brief_summary>The purpose protocol demonstrate safety efficacy single injection new formulation Clostridium Botulinum toxin type A haemagglutinin complex ( BTX A HAC NG ) improve appearance moderate severe glabellar line ( line eyebrow ) assess long term efficacy safety BTX-A-HAC NG repeat injection .</brief_summary>
	<brief_title>Efficacy Safety Botulinum Toxin Type A Haemagglutinin Complex Next Generation ( BTX-A-HAC NG ) Glabellar Lines</brief_title>
	<detailed_description>This multicentre study conduct two period . Subjects first enrol enter double blind ( DB ) period Cycle 1 . Subjects eligible retreatment offer enter open label ( OL ) Cycles 2 5 DB roll-over subject . Once recruitment DB period complete , study enrol additional BTX-na√Øve subject ( hereafter refer OL de novo subject ) OL period Cycle 1 . All OL de novo subject eligible retreatment also offer enter OL Cycles 2 5 . A total 580 subject ( 180 subject randomise DB period additional 400 de novo subject OL period ) plan complete study .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Provision write informed consent prior study related procedure . Male female subject 18 65 year age . Have moderate severe ( Grade 2 3 ) vertical glabellar line maximum frown Baseline ( Day 1 ) , assess ILA use validate 4 point photographic scale . Have moderate severe ( Grade 2 3 ) vertical glabellar line maximum frown Baseline ( Day 1 ) , assess SSA use validate 4point categorical scale . Are dissatisfied dissatisfied ( Grade 2 3 ) glabellar line Baseline ( Day 1 ) , assess subject 's level satisfaction . Have negative pregnancy test ( female childbearing potential ) . No childbearing potential define postmenopausal least 1 year , surgical sterilisation least 3 month enter study , hysterectomy . Have time ability complete study comply study instruction . Previous treatment serotype BTX . Any prior treatment permanent filler upper face include glabellar line area . Any prior treatment dermal filler upper face include glabellar line area within past 3 year and/or skin abrasions/resurfacing ( whatever interventional technic use ) within past 5 year , photo rejuvenation skin/vascular laser intervention within past 12 month . Any planned facial cosmetic surgery study . A history eyelid blepharoplasty brow lift within past 5 year . An inability substantially reduce glabellar line physically spread apart lack capacity frown . An active infection skin problem upper face include glabellar line area ( e.g . acute acne lesion ulcer ) . Use concomitant therapy , investigator 's opinion , would interfere evaluation safety efficacy investigational medicinal product ( IMP ) , include medication affect bleed disorder ( antiplatelet agent and/or anticoagulant give treatment prevention cardio/cerebro vascular disease ) . Pregnant woman , nurse mother , woman plan pregnancy study , believe may pregnant start study . Throughout course study , woman childbearing potential must use reliable form contraception ( e.g . oral contraceptive 12 consecutive week , spermicide condom ) . Treatment experimental drug use experimental device within 30 day prior start study conduct study . Known allergy hypersensitivity component BTXAHAC NG . Clinically diagnose significant anxiety disorder , significant psychiatric disorder ( e.g . depression ) might interfere subject 's participation study . Use medication affect neuromuscular transmission , curarelike non depolarise agent , lincosamides , polymyxin , anticholinesterase aminoglycoside antibiotic , within past 30 day . A history facial nerve palsy . Marked facial asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin . The presence condition ( e.g . neuromuscular disorder disorder could interfere neuromuscular function ) , laboratory find circumstance , judgement investigator , might increase risk subject decrease chance obtain satisfactory data achieve objective study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>